Abstract
Purpose
To evaluate comorbidity, complexity and poor outcomes in patients with sarcoidosis and to compare those scores with a control group.
Methods
218 consecutive patients were diagnosed with sarcoidosis according to the ATS/ERS/WASOG criteria; extrathoracic involvement was evaluated using the 2014 WASOG organ assessment instrument. Sarcoidosis patients were compared with an age- and gender-matched control group of primary care outpatients without sarcoidosis. Comorbidities were assessed retrospectively using the Charlson Comorbidity Index (CCI); complexity was evaluated according to the classification into Clinical Risk Groups (CRG) and severity levels.
Results
The cohort included 142 women and 76 men; the mean age was 47.1 years at diagnosis of sarcoidosis and 55.9 years at the last visit. Patients with a CCI > 1 had a higher frequency of calcium/vitamin D abnormalities (p < 0.001), kidney involvement (p = 0.005) and a higher mortality rate (p < 0.001) compared with patients with a CCI ≤ 1. Patients with a CRG ≥ 6 had a higher frequency of extrathoracic involvement (p = 0.039), calcium/vitamin D abnormalities (p = 0.019) and treatment with glucocorticoids (p = 0.032) compared with patients with a CRG < 6. 11% patients died after a mean follow-up of 102.3 months. Country of birth, kidney involvement and extrathoracic disease were significantly associated with death. Patients with sarcoidosis had a higher frequency of liver (p < 0.001), pulmonary (p = 0.002) and autoimmune disease (p = 0.011) and cancer (p = 0.007) compared with the control group.
Conclusion
We found higher rates of comorbidity and complexity in patients with sarcoidosis compared with a control group. Liver, pulmonary, autoimmune and neoplastic diseases were the main comorbidities found in patients with sarcoidosis.
Similar content being viewed by others
References
Baughman RP, Lower EE, du Bois RM (2003) Sarcoidosis. Lancet 361:1111–1118
Valeyre D, Prasse A, Nunes H, Uzunhan Y, Brillet P-Y, Muller-Quernheim J (2014) Sarcoidosis. Lancet 383:1155–1167
Pereira CAC, Dornfeld MC, Baughman R, Judson MA (2014) Clinical phenotypes in sarcoidosis. Curr Opin Pulm Med 20:496–502
Gerke AK (2014) Morbidity and mortality in sarcoidosis. Curr Opin Pulm Med 20:472–478
Upshur REG, Tracy S (2008) Chronicity and complexity: is what’s good for the diseases always good for the patients? Can Fam Physician 54:1655–1658
Wesemann DR, Costenbader KH, Coblyn JS (2009) Co-existing sarcoidosis, systemic lupus erythematosus and the antiphospholipid antibody syndrome: case reports and discussion from the Brigham and Women’s Hospital Lupus Center. Lupus 18:202–205
Atisha-Fregoso Y, Rivera-Vicencio Y, Baños-Pelaez M, Hernández-Molina G (2015) Main causes and risk factors for hospitalisation in patients with primary Sjögren’s syndrome. Clin Exp Rheumatol 33:721–725
Ofer-Shiber S, Molad Y (2014) Association of the Charlson comorbidity index with renal outcome and all-cause mortality in antineutrophil cytoplasmatic antibody-associated vasculitis. Medicine 93:e152
Bonifazi M, Bravi F, Gasparini S, La Vecchia C, Gabrielli A, Wells AU, Renzoni EA (2015) Sarcoidosis and cancer risk: systematic review and meta-analysis of observational studies. Chest 147:778–791
Tuleta I, Pingel S, Biener L, Pizarro C, Hammerstingl C, Öztürk C, Schahab N, Grohé C, Nickenig G, Schaefer C, Skowasch D (2016) Atherosclerotic vessel changes in Sarcoidosis. Adv Exp Med Biol 910:23–30
Ramos-Casals M, Brito-Zeron P, Garcia-Carrasco M, Font J (2004) Sarcoidosis or Sjogren syndrome? Clues to defining mimicry or coexistence in 59 cases. Medicine 83:85–95
Ramos-Casals M, Mana J, Nardi N, Brito-Zerón P, Xaubet A, Sánchez-Tapias JM, Cervera R, Font J, HISPAMEC Study Group (2005) Sarcoidosis in patients with chronic hepatitis C virus infection: analysis of 68 cases. Medicine 84:69–80
Martusewicz-Boros MM, Boros PW, Wiatr E, Roszkowski-Sliz K (2015) What comorbidities accompany sarcoidosis? A large cohort (n = 1779) patients analysis. Sarcoidosis Vasc Diffus lung Dis 32:115–120
Pohle S, Baty F, Brutsche M (2016) In-hospital disease burden of Sarcoidosis in Switzerland from 2002 to 2012. PLoS ONE 11:e0151940
Nowinski A, Puscinska E, Goljan A, Peradzynska J, Bednarek M, Korzybski D, Kamiński D, Stokłosa A, Czystowska M, Śliwiński P, Górecka D (2015) The influence of comorbidities on mortality in sarcoidosis: a observational prospective cohort study. Clin Respir J. https://doi.org/10.1111/crj.12398
Hunninghake GW, Costabel U, Ando M, Baughman R, Cordier JF, du Bois R, Eklund A, Kitaichi M, Lynch J, Rizzato G, Rose C, Selroos O, Semenzato G, Sharma OP (1999) ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffus lung Dis 16:149–173
Brito-Zerón P, Sellarés J, Bosch X, Hernández F, Kostov B, Sisó-Almirall A, Lopez Casany C, Santos JM, Paradela M, Sánchez M, Ramírez J, Xaubet A, Agustí C, Ramos-Casals M (2016) Epidemiologic patterns of disease expression in sarcoidosis: age, gender and ethnicity-related differences. Clin Exp Rheumatol 34:380–388
Judson MA, Costabel U, Drent M, Wells A, Maier L, Koth L, Shigemitsu H, Culver DA, Gelfand J, Valeyre D, Sweiss N, Crouser E, Morgenthau AS, Lower EE, Azuma A, Ishihara M, Morimoto S, Tetsuo Yamaguchi T, Shijubo N, Grutters JC, Rosenbach M, Li HP, Rottoli P, Inoue Y, Prasse A, Baughman RP, Organ Assessment Instrument Investigators TW (2014) The WASOG Sarcoidosis organ assessment instrument: an update of a previous clinical tool. Sarcoidosis Vasc Diffus lung Dis 31:19–27
Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383
Hughes JS, Averill RF, Eisenhandler J, Goldfield NI, Muldoon J, Neff JM, Gay JC (2004) Clinical Risk Groups (CRGs): a classification system for risk-adjusted capitation-based payment and health care management. Med Care 42:81–90
Jönsen A, Clarke AE, Joseph L, Belisle P, Bernatsky S, Nived O, Bengtsson AA, Sturfelt G, Pineau CA (2011) Association of the Charlson comorbidity index with mortality in systemic lupus erythematosus. Arthritis Care Res 63:1233–1237
Faurschou M, Ahlstrom MG, Lindhardsen J, Baslund B, Obel N (2016) Impact of pre-existing co-morbidities on mortality in granulomatosis with polyangiitis: a cohort study. Rheumatology 55:649–653
Kishor S, Turner ML, Borg BB, Kleiner DE, Cowen EW (2008) Cutaneous sarcoidosis and primary biliary cirrhosis: a chance association or related diseases? J Am Acad Dermatol 58:326–335
Teufel A, Weinmann A, Kahaly GJ, Centner C, Piendl A, Wörns M, Lohse AW, Galle PR, Kanzler S (2010) Concurrent autoimmune diseases in patients with autoimmune hepatitis. J Clin Gastroenterol 44:208–213
Sharma OP (2002) Sarcoidosis and other autoimmune disorders. Curr Opin Pulm Med 8:452–456
Chopra A, Judson MA (2015) How are cancer and connective tissue diseases related to sarcoidosis? Curr Opin Pulm Med 21:517–524
Vaurs C, Ammoury A, Cordel N, Lamant L, Chaufour X, Paul C (2009) Large-vessel granulomatous vasculitis during the course of sarcoidosis: Takayasu’s arteritis? Ann Dermatol Venereol 136:890–893
Malli F, Bargiota A, Theodoridou K, Florou Z, Bardaka F, Koukoulis GN, Gourgoulianis KI, Daniil Z (2012) Increased primary autoimmune thyroid diseases and thyroid antibodies in sarcoidosis: evidence for an under-recognised extrathoracic involvement in sarcoidosis? Hormones 11:436–443
Yao Y, Jiang F, Jin Z (2016) Pancreatic Sarcoidosis in association with Type 1 autoimmune pancreatitis: a case report and literature review. Pancreas 45:e7–e8
Khalid U, Gislason GH, Hansen PR (2014) Sarcoidosis in patients with psoriasis: a population-based cohort study. PLoS ONE 9:e109632
Polychronopoulos VS, Prakash UBS (2009) Airway involvement in sarcoidosis. Chest 136:1371–1380
Thillai M, Potiphar L, Eberhardt C, Pareek M, Dhawan R, Kon OM, Wickremasinghe M, Wells A, Mitchell D, Lalvani A (2012) Obstructive lung function in sarcoidosis may be missed, especially in older white patients. Eur Respir J 39:775–777
Ungprasert P, Srivali N, Wijarnpreecha K, Thongprayoon C, Cheungpasitporn W, Knight EL (2014) Is the incidence of malignancy increased in patients with sarcoidosis? A systematic review and meta-analysis. Respirology 19:993–998
Shu X, Ji J, Sundquist K, Sundquist J, Hemminki K (2011) Survival in cancer patients with previous hospitalization for sarcoidosis: a Swedish population-based cohort study during 1964–2006. Ann Oncol 22:1427–1434
Ji J, Shu X, Li X, Sundquist K, Sundquist J, Hemminki K (2009) Cancer risk in hospitalized sarcoidosis patients: a follow-up study in Sweden. Ann Oncol 20:1121–1126
Mirsaeidi M, Machado RF, Schraufnagel D, Sweiss NJ, Baughman RP (2015) Racial difference in sarcoidosis mortality in the United States. Chest 147:438–449
Varron L, Cottin V, Schott A-M, Broussolle C, Seve P (2012) Late-onset sarcoidosis: a comparative study. Medicine 91:137–143
Mahévas M, Lescure FX, Boffa JJ, Delastour V, Belenfant X, Chapelon C, Cordonnier C, Makdassi R, Piette JC, Naccache JM, Cadranel J, Duhaut P, Choukroun G, Ducroix JP, Valeyre D (2009) Renal sarcoidosis: clinical, laboratory, and histologic presentation and outcome in 47 patients. Medicine 88:98–106
Romer FK (1980) Renal manifestations and abnormal calcium metabolism in sarcoidosis. Q J Med 49:233–247
Neville E, Walker AN, James DG (1983) Prognostic factors predicting the outcome of sarcoidosis: an analysis of 818 patients. Q J Med 52:525–533
Rodrigues SC, Rocha NA, Lima MS, Arakaki JS, Coletta EN, Ferreira RG, Gonzaga LR, Pereira CA (2011) Factor analysis of sarcoidosis phenotypes at two referral centers in Brazil. Sarcoidosis Vasc Diffus lung Dis 28:34–43
Doty JD, Mazur JE, Judson MA (2003) Treatment of corticosteroid-resistant neurosarcoidosis with a short-course cyclophosphamide regimen. Chest 124:2023–2026
Brismar TB, Shams S, Berinder K, Berlin M, Uddén J, Brismar K, Ringertz HG (2015) Glucocorticoids and sarcoidosis: a longitudinal study on the effects on cortical and trabecular bone. Sarcoidosis Vasc Diffus lung Dis 32:63–69
Sweiss NJ, Lower EE, Korsten P, Niewold TB, Favus MJ, Baughman RP (2011) Bone health issues in sarcoidosis. Curr Rheumatol Rep 13:265–272
Sadikot RT, Dore P, Arnold AG (2001) Sarcoidosis and opportunistic infections. South Med J 94:75–77
Judson MA (2016) Corticosteroids in Sarcoidosis. Rheum Dis Clin North Am 42:119–135
Acknowledgements
This study was supported by Grants Fondo de Investigaciones Sanitarias (MRC, INT15/00085) and “Ajut per a la Recerca Josep Font” (PBZ, Hospital Clinic-Barcelona 2012). The authors wish to thank David Buss for his editorial assistance.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Electronic Supplementary Material
Below is the link to the electronic supplementary material.
408_2017_76_MOESM2_ESM.tif
Adjusted survival curves according to the CCI score (< or > 1) (Figure A females, Figure B males). (TIF 6460 KB)
Rights and permissions
About this article
Cite this article
Brito-Zerón, P., Acar-Denizli, N., Sisó-Almirall, A. et al. The Burden of Comorbidity and Complexity in Sarcoidosis: Impact of Associated Chronic Diseases. Lung 196, 239–248 (2018). https://doi.org/10.1007/s00408-017-0076-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00408-017-0076-4